Relay Therapeutics (NASDAQ:RLAY) Insider Sells $11,441.30 in Stock

Relay Therapeutics, Inc. (NASDAQ:RLAY) insider Peter Rahmer sold 1,354 shares of the stock in a transaction that occurred on Wednesday, January 28th. The shares were sold at an average price of $8.45, for a total transaction of $11,441.30. Following the completion of the transaction, the insider owned 276,610 shares of the company’s stock, valued at $2,337,354.50. This trade represents a 0.49% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Peter Rahmer also recently made the following trade(s):

• On Tuesday, January 27th, Peter Rahmer sold 11,684 shares of Relay Therapeutics stock. The stock was sold at an average price of $7.62, for a total value of $89,032.08.

Relay Therapeutics Stock Up 0.8%

RLAY traded up $0.06 during trading on Thursday, reaching $7.71. The stock had a trading volume of 1,788,553 shares, compared to its average volume of 2,246,533. The stock has a 50 day moving average of $7.93 and a two-hundred day moving average of $5.93. The firm has a market capitalization of $1.34 billion, a price-to-earnings ratio of -4.41 and a beta of 1.55. Relay Therapeutics, Inc. has a 1-year low of $1.77 and a 1-year high of $9.04.

Relay Therapeutics (NASDAQ:RLAY) last issued its quarterly earnings results on Thursday, November 6th. The company reported ($0.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.04). On average, research analysts forecast that Relay Therapeutics, Inc. will post -2.55 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the stock. Oppenheimer upgraded shares of Relay Therapeutics from a “market perform” rating to an “outperform” rating and set a $14.00 price objective for the company in a research report on Monday. Weiss Ratings restated a “sell (d-)” rating on shares of Relay Therapeutics in a report on Friday, January 9th. Finally, Wells Fargo & Company upgraded shares of Relay Therapeutics from an “equal weight” rating to an “overweight” rating and lifted their price target for the stock from $6.00 to $13.00 in a research report on Friday, December 12th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Relay Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $16.57.

Institutional Investors Weigh In On Relay Therapeutics

A number of large investors have recently made changes to their positions in RLAY. Pictet Asset Management Holding SA purchased a new stake in shares of Relay Therapeutics in the 4th quarter valued at approximately $127,000. UBS Group AG raised its stake in Relay Therapeutics by 94.4% during the 4th quarter. UBS Group AG now owns 296,017 shares of the company’s stock valued at $2,504,000 after purchasing an additional 143,764 shares during the period. Sanctuary Advisors LLC purchased a new stake in shares of Relay Therapeutics in the fourth quarter valued at $1,203,000. Vanguard Group Inc. boosted its position in shares of Relay Therapeutics by 3.1% in the fourth quarter. Vanguard Group Inc. now owns 9,691,445 shares of the company’s stock worth $81,990,000 after buying an additional 295,701 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of Relay Therapeutics by 20.2% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 57,234 shares of the company’s stock valued at $484,000 after buying an additional 9,613 shares in the last quarter. Institutional investors and hedge funds own 96.98% of the company’s stock.

Key Stories Impacting Relay Therapeutics

Here are the key news stories impacting Relay Therapeutics this week:

• Neutral Sentiment: AAII published an explainer on why RLAY slid ~5.18%, summarizing market reaction and citing recent insider transactions as a driver. AAII Article
• Negative Sentiment: CFO Thomas Catinazzo sold 15,515 shares across Jan. 27–28 (13,820 shares at $7.62 and 1,695 at $8.45), totaling roughly $119k + $14k ≈ $120k in disclosed sales; ownership fell ~5.22% then 0.68%. SEC filing: Catinazzo SEC Filing
• Negative Sentiment: Insider Peter Rahmer sold 13,038 shares across Jan. 27–28 (11,684 at $7.62 and 1,354 at $8.45), about $89k + $11.4k ≈ $100k in sales; his holding decreased ~4.03% then 0.49%. SEC filing: Rahmer SEC Filing
• Negative Sentiment: Insider Donald A. Bergstrom sold 21,581 shares across Jan. 27–28 (18,895 at $7.62 and 2,686 at $8.45), about $144k + $22.7k ≈ $167k in sales; his stake fell ~4.28% then 0.64%. SEC filing: Bergstrom SEC Filing

About Relay Therapeutics

Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins.

The company’s core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening.